Reminder for Grail Investors on Class Action Deadline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Grail's stock plummeted by 50.5% to $50.21 per share on February 20, 2026, after the NHS-Galleri trial failed to meet its primary endpoint, resulting in significant investor losses.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by August 4, 2026, alleging that the company made misleading statements and failed to disclose critical adverse information during the class period from May 13, 2025, to February 19, 2026.
- Management Confidence Issues: The lawsuit claims that management's confidence in the trial's initial results was misplaced, ignoring unreleased trend data, which misled investors regarding the company's prospects.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP, providing necessary contact details for legal support.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 63.740
Low
38.00
Averages
60.86
High
83.71
Current: 63.740
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Grail Investors on Class Action Deadline
- Lawsuit Background: Grail's stock plummeted by 50.5% to $50.21 per share on February 20, 2026, after the NHS-Galleri trial failed to meet its primary endpoint, resulting in significant investor losses.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by August 4, 2026, alleging that the company made misleading statements and failed to disclose critical adverse information during the class period from May 13, 2025, to February 19, 2026.
- Management Confidence Issues: The lawsuit claims that management's confidence in the trial's initial results was misplaced, ignoring unreleased trend data, which misled investors regarding the company's prospects.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP, providing necessary contact details for legal support.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against GRAIL, Inc., alleging violations of federal securities laws on behalf of all investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026.
- False Statements Allegation: The complaint claims that the defendants made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects.
- Investor Rights Protection: Affected investors have until August 4, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, ensuring that investors' rights are protected without upfront costs.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman is recognized for its success in recovering hundreds of millions for investors nationwide, focusing on restoring investor capital and ensuring corporate accountability to uphold market integrity.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duties by its executives, which may lead shareholders to seek corporate reforms and fund recovery.
- Financial Performance Under Scrutiny: A recent securities fraud class action alleges that Badger Meter misled investors into believing its financial performance was driven by sustainable demand, while in reality, it masked weakening demand trends.
- Impact of Declining Performance: Following a series of disappointing quarterly announcements in 2025 and 2026, Badger Meter's stock price experienced significant declines, severely undermining investor confidence in the company's future growth prospects and resulting in substantial losses for shareholders.
- Legal Action Recommendations: Shareholders who hold Badger Meter stock are encouraged to participate in the investigation to seek no-cost corporate reforms and court-approved incentives, aiming to protect their interests and pursue potential compensation.
See More
Class Action Lawsuit Filed Against Grail, Inc.
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) for stock transactions between May 13, 2025, and February 19, 2026, alleging violations of the Securities Exchange Act of 1934 that resulted in substantial investor losses.
- Misleading Trial Results: The lawsuit claims that Grail made false statements regarding its NHS-Galleri trial, asserting a significant reduction in Stage III-IV cancer rates, which was not statistically significant, leading to a stock price drop of over 50% on February 19, 2026.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing the interests of all class members in the lawsuit to ensure their rights are protected.
- Law Firm's Strength: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, demonstrating its significant strength and influence in the securities class action arena.
See More
Grail's Multi-Cancer Early Detection Test Faces Challenges
- Trial Results Disappointment: Grail's Galleri test failed to meet its primary endpoint in the NHS trial, showing no statistically significant reduction in Stage III-IV cancer detection, which has led to a more than 30% decline in stock price in 2026, reflecting market concerns about its future prospects.
- Follow-Up Data Potential: Management anticipates that the 12-month follow-up data from the NHS trial will reveal more undetected cancers, thereby supporting the efficacy of the Galleri test in early cancer detection, which could influence insurance coverage decisions positively.
- Deadly Cancer Detection Trend: Management highlighted a favorable trend in detecting 12 deadly cancers in the NHS trial, with sensitivity significantly higher than for other cancers, which may prompt insurers to reassess the cost-benefit analysis of the Galleri test.
- Positive Predictive Value Advantage: The Galleri test demonstrated positive predictive values of 52% and 60.3% in the NHS and PATHFINDER trials, respectively, indicating its effectiveness in cancer detection, which could attract insurers' attention to its relative cost-effectiveness and drive broader adoption.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc. regarding misleading statements about the NHS-Galleri trial's failure to achieve a statistically significant reduction in Stage III and IV cancers, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs in the class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the primary endpoint was not observed in the NHS-Galleri trial, the stock price plummeted from $101.53 to $50.21 per share, representing a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- Insufficient Disclosure: Grail provided overly optimistic statements about the trial's design being sufficient to demonstrate the primary endpoint's achievability while concealing that the trial period and screening duration were likely inadequate, misleading investors about the trial's true status.
- Investor Rights Protection: Faruqi & Faruqi encourages investors who purchased Grail stock between May 13, 2025, and February 19, 2026, to contact them to discuss their legal rights and seek compensation, ensuring that investors can assert their rights in the class action lawsuit.
See More
Reminder for Grail Investors on Class Action Deadline
- Lawsuit Background: Grail's stock plummeted by 50.5% to $50.21 per share on February 20, 2026, after the NHS-Galleri trial failed to meet its primary endpoint, resulting in significant investor losses.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by August 4, 2026, alleging that the company made misleading statements and failed to disclose critical adverse information during the class period from May 13, 2025, to February 19, 2026.
- Management Confidence Issues: The lawsuit claims that management's confidence in the trial's initial results was misplaced, ignoring unreleased trend data, which misled investors regarding the company's prospects.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP, providing necessary contact details for legal support.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against GRAIL, Inc., alleging violations of federal securities laws on behalf of all investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026.
- False Statements Allegation: The complaint claims that the defendants made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects.
- Investor Rights Protection: Affected investors have until August 4, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, ensuring that investors' rights are protected without upfront costs.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman is recognized for its success in recovering hundreds of millions for investors nationwide, focusing on restoring investor capital and ensuring corporate accountability to uphold market integrity.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duties by its executives, which may lead shareholders to seek corporate reforms and fund recovery.
- Financial Performance Under Scrutiny: A recent securities fraud class action alleges that Badger Meter misled investors into believing its financial performance was driven by sustainable demand, while in reality, it masked weakening demand trends.
- Impact of Declining Performance: Following a series of disappointing quarterly announcements in 2025 and 2026, Badger Meter's stock price experienced significant declines, severely undermining investor confidence in the company's future growth prospects and resulting in substantial losses for shareholders.
- Legal Action Recommendations: Shareholders who hold Badger Meter stock are encouraged to participate in the investigation to seek no-cost corporate reforms and court-approved incentives, aiming to protect their interests and pursue potential compensation.
See More
Class Action Lawsuit Filed Against Grail, Inc.
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) for stock transactions between May 13, 2025, and February 19, 2026, alleging violations of the Securities Exchange Act of 1934 that resulted in substantial investor losses.
- Misleading Trial Results: The lawsuit claims that Grail made false statements regarding its NHS-Galleri trial, asserting a significant reduction in Stage III-IV cancer rates, which was not statistically significant, leading to a stock price drop of over 50% on February 19, 2026.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing the interests of all class members in the lawsuit to ensure their rights are protected.
- Law Firm's Strength: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, demonstrating its significant strength and influence in the securities class action arena.
See More
Grail's Multi-Cancer Early Detection Test Faces Challenges
- Trial Results Disappointment: Grail's Galleri test failed to meet its primary endpoint in the NHS trial, showing no statistically significant reduction in Stage III-IV cancer detection, which has led to a more than 30% decline in stock price in 2026, reflecting market concerns about its future prospects.
- Follow-Up Data Potential: Management anticipates that the 12-month follow-up data from the NHS trial will reveal more undetected cancers, thereby supporting the efficacy of the Galleri test in early cancer detection, which could influence insurance coverage decisions positively.
- Deadly Cancer Detection Trend: Management highlighted a favorable trend in detecting 12 deadly cancers in the NHS trial, with sensitivity significantly higher than for other cancers, which may prompt insurers to reassess the cost-benefit analysis of the Galleri test.
- Positive Predictive Value Advantage: The Galleri test demonstrated positive predictive values of 52% and 60.3% in the NHS and PATHFINDER trials, respectively, indicating its effectiveness in cancer detection, which could attract insurers' attention to its relative cost-effectiveness and drive broader adoption.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc. regarding misleading statements about the NHS-Galleri trial's failure to achieve a statistically significant reduction in Stage III and IV cancers, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs in the class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the primary endpoint was not observed in the NHS-Galleri trial, the stock price plummeted from $101.53 to $50.21 per share, representing a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- Insufficient Disclosure: Grail provided overly optimistic statements about the trial's design being sufficient to demonstrate the primary endpoint's achievability while concealing that the trial period and screening duration were likely inadequate, misleading investors about the trial's true status.
- Investor Rights Protection: Faruqi & Faruqi encourages investors who purchased Grail stock between May 13, 2025, and February 19, 2026, to contact them to discuss their legal rights and seek compensation, ensuring that investors can assert their rights in the class action lawsuit.
See More
